Approval · Notice of Compliance 3935 · 1997
MEGACE: Notice of Compliance 3935
Issued February 6, 1997
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3935
- Date
- February 6, 1997
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: for use in cancer as an antianorexic and anticachectic
- Therapeutic class
- Progestogen/antineoplastic/antianorexic/anticachetic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MEGACE | Not yet assigned | — |
Medicinal ingredients
- MEGESTROL ACETATE 40 MG per TAB
- MEGESTROL ACETATE 160 MG per TAB